Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Interest & Investment Income (2020 - 2025)

Bioventus (BVS) has disclosed Interest & Investment Income for 6 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 41.02% year-over-year to -$5.3 million, compared with a TTM value of -$26.5 million through Dec 2025, up 31.72%, and an annual FY2025 reading of -$26.5 million, up 31.72% over the prior year.
  • Interest & Investment Income was -$5.3 million for Q4 2025 at Bioventus, up from -$6.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.9 million in Q2 2021 and bottomed at -$10.6 million in Q3 2023.
  • Average Interest & Investment Income over 5 years is -$5.6 million, with a median of -$6.8 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income soared 220.79% in 2021, then tumbled 835.4% in 2023.
  • Year by year, Interest & Investment Income stood at -$960000.0 in 2021, then decreased by 14.48% to -$1.1 million in 2022, then crashed by 835.4% to -$10.3 million in 2023, then increased by 12.48% to -$9.0 million in 2024, then soared by 41.02% to -$5.3 million in 2025.
  • Business Quant data shows Interest & Investment Income for BVS at -$5.3 million in Q4 2025, -$6.2 million in Q3 2025, and -$7.5 million in Q2 2025.